<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-97 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-97</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-97</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-8.html">extraction-schema-8</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <p><strong>Paper ID:</strong> paper-b8820446b375d0816aa0b1e3bab05e5e88814d21</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/b8820446b375d0816aa0b1e3bab05e5e88814d21" target="_blank">Advances in Targeted Therapies and Combination Approaches for Melanoma: A Comprehensive Review</a></p>
                <p><strong>Paper Venue:</strong> Quality in Sport</p>
                <p><strong>Paper TL;DR:</strong> The molecular pathways involved in melanoma and therapeutic strategies targeting them are examined, aiming to improve patient outcomes and overcome treatment resistance by understanding genetic alterations and signaling cascades driving melanoma progression.</p>
                <p><strong>Paper Abstract:</strong> Introduction and Purpose: Melanoma, an aggressive malignancy from melanocytes, has a poor prognosis. Despite advances in targeted therapies and immunotherapies, drug resistance remains a challenge. This review examines the molecular pathways involved in melanoma and therapeutic strategies targeting them, aiming to improve patient outcomes and overcome treatment resistance by understanding genetic alterations and signaling cascades driving melanoma progression. 
State of Knowledge: Melanoma arises from genetic predisposition and UV radiation exposure, involving mutations in pathways like RAS/RAF/MAPK and PI3K/AKT. Targeted therapies, such as BRAF and MEK inhibitors, are effective, especially in BRAF-mutant patients. However, resistance mechanisms, including alternative pathway activation and immune evasion, limit their long-term success. Combination therapies with immunotherapies show promise in overcoming resistance. Emerging targets like NRAS, c-KIT, and c-MET offer new treatment possibilities. Ongoing challenges include identifying biomarkers for patient stratification and managing treatment-related toxicity. 
Conclusions: Understanding the molecular mechanisms of melanoma is crucial for advancing therapies. Targeted therapies and combination approaches have improved outcomes, especially in advanced cases. However, challenges like treatment resistance and toxicity require ongoing research. By exploring signaling pathways and new targets, treatment efficacy and durability can be enhanced. Continued research and clinical trials are essential to translate these advancements into practice, improving survival rates and quality of life for melanoma patients.</p>
                <p><strong>Cost:</strong> 0.016</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e97.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e97.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Spartalizumab + Dabrafenib + Trametinib</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Spartalizumab combined with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A clinical combination of an (immuno)therapy agent (spartalizumab) with dual targeted inhibition of the MAPK pathway (dabrafenib + trametinib) mentioned in this review as an example of combining immunotherapy and targeted therapy in BRAF-mutant melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Advances in Targeted Therapies and Combination Approaches for Melanoma: A Comprehensive Review</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>primary_immunotherapy</strong></td>
                            <td>spartalizumab</td>
                        </tr>
                        <tr>
                            <td><strong>immunotherapy_class</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_type</strong></td>
                            <td>acquired/late resistance (general discussion in review)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanism</strong></td>
                            <td>immune evasion and alternative pathway activation (reviewed generally as mechanisms limiting long-term success of immunotherapies)</td>
                        </tr>
                        <tr>
                            <td><strong>combination_strategy_name</strong></td>
                            <td>Immunotherapy + BRAF inhibitor + MEK inhibitor</td>
                        </tr>
                        <tr>
                            <td><strong>combination_agents</strong></td>
                            <td>spartalizumab + dabrafenib + trametinib (as cited in the review's references)</td>
                        </tr>
                        <tr>
                            <td><strong>combination_rationale</strong></td>
                            <td>Concurrent targeting of oncogenic BRAF/MEK signaling (to reduce tumor growth driven by MAPK pathway) together with an immunotherapy agent to engage anti-tumor immunity and counteract immune-evasion and alternative pathway–mediated resistance.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>phase III clinical trial (referenced in the review; Dummer et al. J Clin Oncol. 2022 listed in references)</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>BRAF V600-mutant unresectable or metastatic melanoma (as stated in the referenced trial title)</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_outcomes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td>BRAF V600 mutation status (review emphasizes BRAF-mutant patients benefit from BRAF/MEK inhibitors)</td>
                        </tr>
                        <tr>
                            <td><strong>timing_sequence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_safety</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_monotherapy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overcomes_resistance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Advances in Targeted Therapies and Combination Approaches for Melanoma: A Comprehensive Review', 'publication_date_yy_mm': '2024-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e97.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e97.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Immunotherapy + targeted therapy (general)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Combination of immunotherapy with targeted therapies (general strategy, e.g., anti‑PD‑1 + BRAF/MEK inhibitors)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A broadly discussed strategy in the review: combining immune checkpoint–based immunotherapies with targeted inhibitors (such as BRAF and MEK inhibitors) to improve response durability and overcome mechanisms of late or acquired resistance in melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Advances in Targeted Therapies and Combination Approaches for Melanoma: A Comprehensive Review</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>primary_immunotherapy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immunotherapy_class</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_type</strong></td>
                            <td>acquired/late resistance (review explicitly cites late/acquired resistance as a challenge)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanism</strong></td>
                            <td>alternative pathway activation and immune evasion (explicitly named in the abstract as mechanisms limiting long-term success)</td>
                        </tr>
                        <tr>
                            <td><strong>combination_strategy_name</strong></td>
                            <td>Immunotherapy combined with targeted therapy (e.g., anti‑PD‑1/other immunotherapies + BRAF/MEK inhibitors)</td>
                        </tr>
                        <tr>
                            <td><strong>combination_agents</strong></td>
                            <td>examples referenced in the review include BRAF inhibitors and MEK inhibitors (dabrafenib + trametinib) combined with immunotherapy agents (unnamed in abstract; trial using spartalizumab referenced); the review also cites literature on combining immunotherapy with targeted agents broadly.</td>
                        </tr>
                        <tr>
                            <td><strong>combination_rationale</strong></td>
                            <td>To simultaneously inhibit oncogenic signaling pathways that drive tumor growth and the molecular routes that produce resistance, while activating anti-tumor immune responses — thereby addressing both tumor-intrinsic pathway reactivation and immune-evasion mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review summarizing clinical and preclinical evidence (references include clinical trials and preclinical studies)</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>review references BRAF‑mutant patients and metastatic melanoma broadly; specific trials in references pertain to BRAF V600‑mutant unresectable/metastatic melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_outcomes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td>BRAF mutation status noted as important for patient selection; review also notes the ongoing challenge of identifying biomarkers for patient stratification (no specific predictive biomarkers reported in the text provided)</td>
                        </tr>
                        <tr>
                            <td><strong>timing_sequence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_safety</strong></td>
                            <td>The review notes treatment-related toxicity as an ongoing challenge when using combination approaches (no specific rates given in the provided text).</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_monotherapy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overcomes_resistance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Advances in Targeted Therapies and Combination Approaches for Melanoma: A Comprehensive Review', 'publication_date_yy_mm': '2024-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma <em>(Rating: 2)</em></li>
                <li>Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma <em>(Rating: 2)</em></li>
                <li>Targeted agents and immunotherapies: optimizing outcomes in melanoma <em>(Rating: 2)</em></li>
                <li>Clinical Development of BRAF plus MEK Inhibitor Combinations <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>